Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass

Heart

Volumn 89, Issue 5, 2003, Pages 538-543

  Chello, Massimo ^a   Mastroroberto, P ^b   Patti, G ^a   D'Ambrosio, A ^a   Cortez Morichetti, M ^a   Di Sciascio, G ^a   Covino, E ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PADGEM PROTEIN; SIMVASTATIN; STATIN;

ADULT; ARTICLE; BLOOD VESSEL PERMEABILITY; CARDIOPULMONARY BYPASS; CELL INTERACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; LEUKOCYTE; MALE; MEDIATOR RELEASE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM;

EID: 0037407254     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.5.538     Document Type: Article

References (40)

1. Verrier ED, Boyle EM. Endothelial cell injury in cardiovascular surgery: an overview. Ann Thorac Surg 1997;64:S2-8.
2. Asimakopoulos G, Taylor KM. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg 1998;66:2135-44.
3. Lefer AM, Tsao PS, Lefer DJ, et al. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J 1991;5:2029-34.
4. Pinsky DJ, Naka Y, Liao H, et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. J Clin Invest 1996;97:493-500.
5. Asimakopoulos G. Systemic inflammation and cardiac surgery: an update. Perfusion 2001;16:353-60.
6. Treacher DF, Sabbato M, Brown KA, et al. The effects of leucodepletion in patients who develop the systemic inflammatory response syndrome following cardiopulmonary bypass. Perfusion 2001;16(suppl):67-73.
7. Kawahito K, Kobayashi E, Ohmori M, et al. Enhanced responsiveness of circulatory neutrophils after cardiopulmonary bypass: increased aggregability and superoxide producing capacity. Artif Organs 2000;24:37-42.
8. Menaschè P. The systemic factor: the comparative roles of cardiopulmonary bypass and off pump surgery in the genesis of patient injury during and following cardiac surgery. Ann Thorac Surg 2001;72:S2260-6.
9. Hayashi Y, Saewa Y, Fukuyama N, et al. Inducible nitric oxide production is an adaptation to cardiopulmonary bypass-induced inflammatory response. Ann Thorac Surg 2001;72:149-55.
10. Engelman DT, Watanabe M, Engelman RM, et al. Constitutive nitric oxide release is impaired after ischemia and reperfusion. J Thorac Cardiovasc Surg 1995;110:1047-53.
11. Kubes P, Suzuki M, Granger D. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-5.
12. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am J Hypertens 2001;14:44-54S.
13. Gauthier TW, Davenpeck KL, Lefer AM. Nitric oxide attenuates leukocyte endothelial interaction via P-selectin in splanchnic ischemia-reperfusion. Am J Physiol 1994;26:G562-8.
14. Oyama J, Shimokawa H, Momii H, et al. Role of nitric oxide and peroxynitrite in the cytokine induced sustained myocardial dysfunction in dogs in vivo. J Clin Invest 1998;110:2207-14.
15. Worrall NK, Chang K, Lejeunne WS, et al. TNF-alpha causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and independent mechanism. Am J Physiol 1997;273:H2565-74.
16. Murphy RT, Foley JB, Mulvihill N, et al. Impact of pre-existing statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am J Cardiol 2001;87:446-8.
17. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
18. Datani MI, Elnicki M, Jain AC, et al. Effect of preoperative statin therapy and cardiac outcome after coronary artery bypass grafting. Am J Cardiol 2000;86:1128-30.
19. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concept for cardiovascular disease. Cardiovasc Res 2001;49:281-7.
20. Miller SJ. Emerging mechanisms for secondary cardioprotective effects of statins. Cardiovasc Res 2001;52:5-7.
21. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-19.
22. Pruefer D, Scaliia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999;19:2894-900.
23. Chello M, Mastroroberto P, Malta E, et al. Inhibition by dipyridamole of neutrophil adhesion to vascular endothelium during coronary bypass surgery. Ann Thorac Surg 1999;67:1277-82.
24. Ma X, Weyrich AS, Lefer DJ. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 1993;77:403-12.
25. Chello M, Mastroroberto P, Marchese AR, et al. Nitric oxide inhibits neutrophil adhesion during experimental extracorporeal circulation. Anesthesiology 1998;89:443-8.
26. Chester AH, Morrison KJM, Yacoub MH. Expression of vascular adhesion molecules in saphenous vein coronary bypass. Ann Thorac Surg 1998;65:1685-9.
27. Florens E, Salvi S, Peynet J, et al. Can statins reduce inflammatory response to cardiopulmonary bypass? A clinical study. J Card Surg 2001;16:232-9.
28. Chello M, Mastroroberto P, Perticone F, et al. Nitric oxide modulation of neutrophil-endothelium interaction: difference between arterial and venous coronary bypass grafts. J Am Coll Cardiol 1998;31:823-6.
29. Brull JD, Sanders J, Rumley A, et al. Statin therapy and the acute inflammatory response after coronary artery bypass grafting. Am J Cardiol 2001;88:431-3.
30. Weis M, Pehlivanli S, Meiser BM, et al. Simvastatin treatment is associated with improvement in coronary endothelium function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001;38:814-18.
31. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.
32. Lefer AM, Campbell B, Shin YK, et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999;100:178-84.
33. Weber C, Erl W, Weber KSC, et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-17.
34. Patel KD, Zzimmerman GA, Prescott SM, et al. Oxygen radicals induce human endothelial cells to express MP-140 and bind neutrophils. J Cell Biol 1991;112:749-59.
35. Closse C, Seigneur M, Renard M, et al. Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. Thromb Res 1997;85:159-64.
36. Kurose I, Anderson DC, Miyasaka M, et al. Molecular determinants of reperfusion-induced leukocyte adhesion and vascular protein leakage. Circ Res 1994;74:336-43.
37. Laufs U, La fata V, Liao JK. Inhibition of 3-hydroxyy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down regulation of endothelial nitric oxide synthase. J Biol Chem 1997;272:31725-9.
38. Wassmann S, Laufs U, Baumerr AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-7.
39. Endres M, Laufs U, Huamg Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-5.
40. Pinsky DJ, Oz MC, Liao S, et al. Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model. J Clin Invest 1993;92:2994-3002.